An observational study in Primary Myelofibrosis, Secondary Myelofibrosis and Post-polycythemia Vera Myelofibrosis, sponsored by iOMEDICO AG. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-05.
Sponsored by iOMEDICO AG · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 75 studies in Primary Myelofibrosis with a site in Germany — 15 open to participants now, 29 under way, 9 of them phase 3. Primary Myelofibrosis · Germany.
Among the 75 studies in Primary Myelofibrosis with a site in Germany, this one is one of 4 that started in 2026, is one of 5 observational ones, reaches primary completion later than 27 of the 28 other live ones, and was the 71st registered.
628 studies on the registry are indexed under Primary Myelofibrosis; 126 are open to participants now.
Browse Primary Myelofibrosis studies →15 of the 75 studies in Primary Myelofibrosis with a site in Germany are open now. Recruiting first, the newest first:
Takeda · Sites in Germany, United States, Argentina and 28 more countries
Ages 18+
Novartis Pharmaceuticals · Sites in Germany, United States, Argentina and 21 more countries
Ages 18+
Incyte Corporation · Sites in Germany, United States, Australia and 8 more countries
Ages 18+
Incyte Corporation · Sites in Germany, United States, Australia and 2 more countries
Ages 18+
GlaxoSmithKline · Sites in Germany, United States, Canada and 3 more countries
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 11 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
75 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 33 · Phase 3 24 · Phase 4 1
First in 1999; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 125 across 73 observational studies indexed under Primary Myelofibrosis.
Median enrollment 116 across the 70 interventional studies, 617 across the 5 observational. Of the 45 that completed or were terminated, 28 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
63 of 75 have an industry lead sponsor. The 10 most frequent:
iOMEDICO AG is the lead sponsor of 53 studies on the registry; 14 are open to participants now.
iOMEDICO AG has 1 study filed under Primary Myelofibrosis — fewer than ten, so there is no comparison to draw.
7 of the studies in Primary Myelofibrosis with a site in Germany that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06479135Phase 3Kartos Therapeutics, Inc.Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib | 2026-12-31 |
| NCT01761968ItalfarmacoLong-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative Neoplasms | 2026-12 |
| NCT03441113GlaxoSmithKlineExtended Access of Momelotinib in Adults With Myelofibrosis | 2026-12-11 |
| NCT04041050AbbVieA Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm | 2026-12-31 |
| NCT06517875GlaxoSmithKlineStudy of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis | 2027-03-16 |
Add all 7 to your calendar (.ics) → With an account.
Among the 75 studies in Primary Myelofibrosis with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study, a tumor research platform, to document uniform data on characteristics, molecular diagnostics, treatment and course of disease and to collect patient-reported outcomes for patients with primary and secondary myelofibrosis and anemia in Germany.
RHODOLITE is a national, prospective, open-label, longitudinal, non-interventional multicenter cohort study (research platform) to describe treatment in routine clinical practice of myelofibrosis patients in routine care in Germany.
RHODOLITE will follow patients for up to three years with the aim to identify common therapeutic sequences and changes in the treatment of the disease. At inclusion, data in patient characteristics, comorbidities, tumor characteristics and previous treatments are collected. During the course of observation data on all systemic treatments and outcome are documented.
Health-related quality of life (HRQoL) will be evaluated for up to three years.
The RHODOLITE project is a joint project with the German Study Group for Myeloproliferative Neoplasms (GSG-MPN) and its GSG-MPN Bioregistry (NCT03125707). Details on treatment and outcome will be collected in RHODOLITE for up to three years, while long-term follow-up for a minimum of additional five years will be performed in the GSG-MPN Bioregistry.
Adult patients with primary myelofibrosis or post-polycythemia vera or post-essential thrombocythemia myelofibrosis (MF) with anemia
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Documentation of systemic treatment for MF and therapy sequences
Types and frequencies of systemic treatment for MF during observation time.
Time frame: 3 years per patient
Hematologic response
Frequencies of hematologic response (improved, stable, worsened) per line of treatment
Time frame: 3 years per patient
Splenic response
Frequencies of splenic response (improved, stable, worsened) per line of treatment
Time frame: 3 years per patient
Overall response rate (ORR)
Documentation of ORR per line of treatment
Time frame: 3 years per patient
Progression free survival (PFS)
Documentation of PFS per line of treatment
Time frame: 3 years per patient
Overall survival
Documentation of OS per line of treatment
Time frame: 3 years per patient
Health-related quality of life (Patient-reported outcome, PRO)
European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire (EORTC QLQ-C30, the lower the score the better the QoL)
Time frame: 3 years per patient
Assessment of Myelofibrosis-related symptoms
Myelofibrosis Symptom Assessment form (MFSAF) questionnaire 7-day Recall
Time frame: 3 years per patient
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2026 (actual). Primary completion is estimated for Sep 2031, 67 months after the start.
Of 23 observational studies under Primary Myelofibrosis, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 119. This study's planned 67 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.